Gabapentin is a prescription medication used to treat epilepsy and nerve pain. It is not typically associated with a "street value" in the same way as illicit drugs, as it is a controlled substance available through legal medical channels. However, like many prescription medications, gabapentin can be misused or diverted for non-medical purposes.
How is Gabapentin Misused?
Gabapentin misuse can occur when individuals take the drug without a prescription, in higher doses than prescribed, or by routes other than intended. It is sometimes used recreationally, often in combination with other substances like opioids or alcohol, to enhance their effects or to manage withdrawal symptoms from other drugs [1]. This combination use can be particularly dangerous and increase the risk of overdose [1].
What are the Risks of Gabapentin Misuse?
Misuse of gabapentin carries significant risks, including the potential for dependence and withdrawal symptoms if use is stopped abruptly [1]. Adverse effects can include dizziness, drowsiness, and impaired coordination, which can increase the risk of accidents [1]. When combined with other central nervous system depressants, the risk of respiratory depression and overdose is substantially elevated [1].
Why is Gabapentin Prescribed?
Gabapentin is a medication prescribed for specific medical conditions. It is primarily used to manage partial seizures in epilepsy and to treat neuropathic pain, such as that associated with postherpetic neuralgia (nerve pain after shingles) and diabetic neuropathy [1]. It works by affecting chemicals and nerves in the body that are involved in causing seizures and pain.
What are the Legal Restrictions on Gabapentin?
Gabapentin is a Schedule V controlled substance under the U.S. Controlled Substances Act, meaning it has a low potential for abuse relative to other controlled substances. However, its potential for misuse has led to increased scrutiny and scheduling in many states [2]. Prescribers and pharmacists are required to follow specific regulations for dispensing and monitoring its use [2].
Sources:
1. DrugPatentWatch.com
2. U.S. Drug Enforcement Administration